Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Full data suggest a new strategy for the
Ad hoc announcement pursuant to Art. 53 LR
Results from all 161 patients at the 6-week primary endpoint show a statistically significant improvement over baseline in all
Presentation will include full data from the six-month interim timepoint from the cohort of the first 100 patients randomized in study 014/015, a Phase II trial evaluating
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, March 14, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
Ad hoc announcement pursuant to Art. 53 LR
Highly compelling, statistically significant, clinically meaningful improvement in assessments of symptoms of psychosis, disease
Ad hoc announcement pursuant to Art. 53 LR
Statistically significant, clinically meaningful improvements over baseline were seen across efficacy endpoints after six
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, September 15, 2022, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a
Milan, Italy, July 1, 2022 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for
Ad hoc announcement pursuant to Art. 53 LR
Interim results show improved symptoms of psychosis in patients with chronic TRS
Study 014 represents first international trial of a New
Milan, Italy – April 5, 2022 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
